Functionalized microcarriers for Enhanced CAR T cell manufacturing by Dwarshuis, Nate et al.
FUNCTIONALIZED MICROCARRIERS FOR ENHANCED CAR T CELL MANUFACTURING 
 
Nate Dwarshuis, Department of Biomedical Engineering, Georgia Institute of Technology and Emory University 
ndwarshuis3@gatech.edu 
Hannah Wilson Song, Department of Biomedical Engineering, Georgia Institute of Technology and Emory 
University 
Anokhi Patel, Department of Biomedical Engineering, Georgia Institute of Technology and Emory University 
Krishnendu Roy, Department of Biomedical Engineering, Georgia Institute of Technology and Emory University 
 
 
Key Words: microcarrier chimeric antigen receptor bioreactor 
 
Adoptive cell therapy using chimeric antigen receptor (CAR) T cells has shown immense promise in treating 
cancer. In 2017, Novartis and Kite Pharma both acquired FDA approval for their CAR T cell therapies targeted 
toward B cell malignancies. Despite these successes, manufacturing high-quality T cells at scale has proven 
challenging. Notably, current processes rely on bead-based expansion and suspension-cell bioreactors, which 
do not recapitulate the high cell density and robust signaling found in the lymph nodes. 
 
We hypothesized that recreating the human lymph 
node using functionalized biomaterials could lead to 
increased T cell expansion. This strategy involved 
functionalizing macroporous, gelatin microcarriers 
(commonly used throughout the bioprocess industry) 
with CD3/CD28 antibodies to provide activation 
signals. Cells can adhere to these antibodies and 
grow along the surface and throughout the interior, 
enabling efficient auto/paracrine signaling. Gelatin, 
as a collagen derivative, also provides matrix signals. 
 
Primary human T cells were incubated with carriers 
or conventional magnetic activation beads. Carriers 
cultures showed a 3-fold increase at the 25:1 ratio as 
compared to bead cultures (fig 1a), indicating that 
microcarriers can provide superior expansion if 
optimized for culture conditions. Furthermore, the 
phenotype of microcarrier-expanded T cells had a 
greater frequency of CD62L+CCR7+ T cells than 
beads, indicating higher frequency of memory T 
cells (fig 1b). This trend held true across multiple 
experiments and donors, with carriers producing 
11% more memory cells than average. The functionality of memory T cells was confirmed using a CCL21 
transwell assay (fig 1c). We also transfected T cells with an anti-CD19 CAR lentivirus and confirmed anti-tumor 
functionality after 14 days of expansion using a CD107a degranulation assay. 
 
We further hypothesized that the microcarrier culture could be optimized using design of experiments (DOE) 
methodology to interrogate meaningful process parameters. The effect of IL2 concentration, initial cell density, 
media type, activation signal strength, and microcarrier concentration on the resulting fold change and memory 
phenotype were investigated. Linear regression showed that all factors except initial cell density had a 
significant effect on fold change, indicating that our process is not dependent on obtaining a fixed number of 
cells from patients. Furthermore, we found that only IL2 had an effect on memory phenotype, where an optimum 
was found at an intermediate setting. In summary, this information is useful in industrial settings where the 
concern is producing high quality cells with minimal resources. 
 
We have demonstrated that microcarriers can provide robust expansion of high-quality memory T cells 
compared to state-of-the-art methods while maintaining anti-tumor functionality. Furthermore, we demonstrated 
that DOE methodology can be meaningfully applied to determine optimal process parameters. Further studies 




Figure 1 - a) fold change after 14 days b) surface 
expression of CCR7/CD62L c) chemotaxis transwell assay 
